Kirilys Therapeutics Acquires ASN-004, a 5T4-targeting Antibody Drug Conjugate being evaluated in Ph1 Oncology
Ongoing Phase 1 clinical study is evaluating the safety, pharmacokinetics, and preliminary efficacy of ASN-004 in treatment refractory solid tumors San Francisco, CA, September 1, 2022 — Kirilys Therapeutics, Inc., a multi-asset biotechnology company founded by investment firm Catalys Pacific and supported by Lightspeed Venture Partners, completed the acquisition of ASN-004 from Asana Biosciences, Inc. Kirilys plans […]